

# CITATION REPORT

List of articles citing

## Derangement of immune responses by myeloid suppressor cells

DOI: 10.1007/s00262-003-0443-2

Cancer Immunology, Immunotherapy, 2004, 53, 64-72.

**Source:** <https://exaly.com/paper-pdf/37019261/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
302	High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. <b>2004</b> , 64, 6337-43		420
301	Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. <b>2004</b> , 64, 2205-11		259
300	TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. <b>2004</b> , 4, 675-87		279
299	Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. <b>2004</b> , 6, 409-21		940
298	Regulation of immune responses by L-arginine metabolism. <b>2005</b> , 5, 641-54		1294
297	T cell expansion is regulated by activated Gr-1+ splenocytes. <b>2005</b> , 235, 39-45		8
296	Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. <b>2005</b> , 35, 3533-44		115
295	The interplay between innate and adaptive immunity regulates cancer development. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 1143-52	7.4	67
294	Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 1137-42	7.4	97
293	Modulation of antitumor responses by dendritic cells. <b>2005</b> , 26, 329-41		15
292	Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. <b>2005</b> , 11, 6713-21		796
291	Tumor inflammatory angiogenesis and its chemoprevention. <b>2005</b> , 65, 10637-41		162
290	Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. <b>2005</b> , 174, 636-45		375
289	CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. <b>2005</b> , 175, 8200-8		235
288	Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. <b>2005</b> , 174, 6095-104		118
287	Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. <b>2005</b> , 65, 11743-51		256
286	Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. <b>2005</b> , 102, 4185-90		253

285	Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. <b>2005</b> , 12, 1-17	64
284	A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. <b>2005</b> , 202, 1627-33	240
283	Cancer immunoprevention. <b>2005</b> , 1, 57-66	42
282	Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?. <b>2005</b> , 5, 463-76	54
281	Inflammation-associated cancer: NF-kappaB is the lynchpin. <b>2005</b> , 26, 318-25	239
280	Cancer rejection by the immune system: Forcing the check-points of tumor immune escape. <b>2005</b> , 2, 191-197	1
279	Towards a therapeutic breast cancer vaccine: the next steps. <b>2005</b> , 4, 831-41	3
278	The human T cell response to melanoma antigens. <b>2006</b> , 92, 187-224	49
277	Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. <b>2006</b> , 176, 284-90	430
276	Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. <b>2006</b> , 66, 1123-31	1043
275	Tumor stroma and regulation of cancer development. <b>2006</b> , 1, 119-50	750
274	Cancer vaccines: preclinical studies and novel strategies. <b>2006</b> , 95, 115-45	53
273	Effects of the tumor microenvironment on the efficacy of tumor immunotherapy. <b>2006</b> , 35, 359-94	13
272	Attenuation of murine lysosomal storage disease by allogeneic neonatal bone marrow transplantation using costimulatory blockade and donor lymphocyte infusion without myeloablation. <b>2006</b> , 119, 166-79	4
271	Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. <b>2006</b> , 42, 751-9	153
270	Future directions for vaccine-based therapies. <b>2006</b> , 24, 448-55	3
269	Cytomegalovirus MCK-2 controls mobilization and recruitment of myeloid progenitor cells to facilitate dissemination. <b>2006</b> , 107, 30-8	64
268	T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease. <b>2006</b> , 1, 191-208	8

267	Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. <b>2006</b> , 59, 902-9; discussion 909-10	34
266	Dendritic Cells in Human Cancer. 1081-1092	
265	Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. <b>2006</b> , 118, 261-70	44
264	Paradoxical roles of the immune system during cancer development. <b>2006</b> , 6, 24-37	1682
263	Vaccines for tumour prevention. <b>2006</b> , 6, 204-16	256
262	Challenges for cancer vaccine development. <b>2006</b> , 58, 902-15	27
261	The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. <b>2006</b> , 25, 387-408	427
260	Tumor macrophage redox and effector mechanisms associated with hypoxia. <b>2006</b> , 41, 1621-8	15
259	Vaccines in renal cell carcinoma. <b>2006</b> , 33, 614-24	16
258	Toll-like receptors, inflammation and cancer. <b>2006</b> , 16, 32-7	112
257	Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. <b>2006</b> , 16, 53-65	615
256	Escape from immune- and nonimmune-mediated tumor surveillance. <b>2006</b> , 16, 16-31	46
255	Chronic inflammation, immunosuppression and cancer: new insights and outlook. <b>2006</b> , 16, 80-8	99
254	Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. <b>2006</b> , 18, 1-9	86
253	The inflammatory tumor microenvironment and its impact on cancer development. <b>2006</b> , 13, 118-137	161
252	Cyclooxygenase-2 inhibition augments the efficacy of a cancer vaccine. <b>2006</b> , 12, 214-22	77
251	Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. <b>2006</b> , 12, 4794-803	90
250	Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1alpha. <b>2006</b> , 80, 96-106	33

249	CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. <b>2006</b> , 12, 3435-43	62
248	CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. <b>2006</b> , 66, 6807-15	264
247	CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. <b>2006</b> , 66, 3869-75	49
246	Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. <b>2006</b> , 12, 2359s-2365s	30
245	Mac-1+ cells are the predominant subset in the early hepatic lesions of mice infected with Francisella tularensis. <b>2006</b> , 74, 6590-8	31
244	Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. <b>2006</b> , 79, 652-62	51
243	Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye. <b>2006</b> , 177, 1599-608	25
242	Innovations and challenges in melanoma: summary statement from the first Cambridge conference. <b>2006</b> , 12, 2291s-2296s	14
241	The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. <b>2007</b> , 179, 5071-81	70
240	Inflammation and lung carcinogenesis: applying findings in prevention and treatment. <b>2007</b> , 7, 1405-21	63
239	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-Arginine Metabolism in Immune Modulation. <b>2007</b> , 369-399	
238	Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. <b>2007</b> , 8, 209-16	53
237	Reversal of tumor-mediated immunosuppression. <b>2007</b> , 13, 727s-732s	79
236	Indoleamine 2,3-dioxygenase in hematopoietic stem cell transplantation. <b>2007</b> , 8, 267-72	8
235	Sensors of ionizing radiation effects on the immunological microenvironment of cancer. <b>2007</b> , 83, 819-25	88
234	Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. <b>2007</b> , 6, 880-5	52
233	Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. <b>2007</b> , 67, 10019-26	499
232	Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. <b>2007</b> , 18, 226-32	215

231	Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. <b>2007</b> , 67, 4783-9	74
230	The Terminology Issue for Myeloid-Derived Suppressor Cells. <b>2007</b> , 67, 426-426	10
229	Formalin-fixed Staphylococcus aureus particles prevent allergic sensitization in a murine model of type I allergy. <b>2007</b> , 144, 183-96	14
228	Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics. <b>2007</b> , 3, 174-193	7
227	Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. <b>2007</b> , 109, 4336-42	238
226	Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. <b>2007</b> , 25, 2546-53	549
225	CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. <b>2007</b> , 252, 86-92	258
224	Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. <b>2007</b> , 7, 140-51	112
223	Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. <b>2007</b> , 67, 4507-13	567
222	Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. <b>2007</b> , 9, 212	475
221	Smart adjuvants. <b>2007</b> , 6, 391-400	35
220	Tumor-Associated Myeloid-Derived Suppressor Cells. <b>2007</b> , 309-331	1
219	Tumor microenvironment: the role of the tumor stroma in cancer. <b>2007</b> , 101, 805-15	443
218	Immune cells as anti-cancer therapeutic targets and tools. <b>2007</b> , 101, 918-26	18
217	Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. <b>2007</b> , 14, 1-11	52
216	The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. <b>2007</b> , 88, 351-60	136
215	Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice. <b>2007</b> , 98, 882-9	16
214	Pretransplant treatment of donors with immunomodulators to control graft-versus-host disease (GVHD) in transplant recipients. <b>2007</b> , 35, 748-56	7

213	Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. <b>2007</b> , 82, 12-24		170
212	Multipotency of CD11b <sup>high</sup> Gr-1 <sup>+</sup> immature myeloid cells accumulating in oral squamous cell carcinoma-bearing mice. <b>2007</b> , 43, 586-92		7
211	Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. <b>2007</b> , 67, 10501-10		157
210	A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 973-84	7.4	27
209	Inflammatory cell infiltration of tumors: Jekyll or Hyde. <b>2007</b> , 26, 373-400		237
208	Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 1493-504	7.4	94
207	Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 1531-9	7.4	24
206	Opposing effects of fibrosarcoma cell-derived IL-1 alpha and IL-1 beta on immune response induction. <b>2008</b> , 123, 134-45		27
205	Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. <b>2008</b> , 66, 208-17		102
204	Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. <b>2008</b> , 222, 162-79		508
203	Polarized immune responses differentially regulate cancer development. <b>2008</b> , 222, 145-54		146
202	B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. <b>2008</b> , 129, 471-81		82
201	Dendritic cells as immune regulators: the mouse model. <b>2008</b> , 12, 1909-14		13
200	Role of myeloid cells in tumor angiogenesis and growth. <b>2008</b> , 18, 372-8		131
199	Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. <b>2008</b> , 6, 26		14
198	Dendritic cells in cancer immunotherapy. <b>2008</b> , 99, 363-407		55
197	Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. <b>2008</b> , 46, 258-68		62
196	Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. <b>2008</b> , 31, 354-61		133

195	Role of arginine metabolism in immunity and immunopathology. <b>2007</b> , 212, 795-812	114
194	Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases. <b>2008</b> , 26, 241-9	3
193	Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. <b>2008</b> , 68, 5439-49	515
192	CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy. <b>2008</b> , 14, 973-984	33
191	Dendritic cells and cytokines in immune rejection of cancer. <b>2008</b> , 19, 93-107	52
190	Immune consequences of protracted host-tumor interactions in a transgenic mouse model of mammary carcinoma. <b>2008</b> , 26, 237-49	6
189	Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. <b>2008</b> , 181, 3291-300	109
188	Gr-1(+)CD11b(+) cells as an accelerator of sepsis stemming from <i>Pseudomonas aeruginosa</i> wound infection in thermally injured mice. <b>2008</b> , 83, 1354-62	19
187	Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. <b>2008</b> , 180, 7898-906	216
186	Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. <b>2008</b> , 83, 64-70	784
185	Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. <b>2008</b> , 111, 219-28	270
184	Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. <b>2008</b> , 205, 1687-700	96
183	Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. <b>2008</b> , 111, 5637-45	129
182	Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. <b>2009</b> , 4, e7669	138
181	Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. <b>2009</b> , 182, 240-9	558
180	Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. <b>2009</b> , 183, 117-28	36
179	Immunoregulation of GVHD by triggering the innate immune system with CpG. <b>2009</b> , 2, 443-53	4
178	Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. <b>2009</b> , 182, 5498-506	25



177	Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. <b>2009</b> , 69, 5996-6004	212
176	Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. <b>2009</b> , 8, 1761-71	127
175	Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. <b>2009</b> , 8, 3319-27	54
174	Chemokine-chemokine receptors in cancer immunotherapy. <b>2009</b> , 1, 109-27	21
173	Promising novel immunotherapies and combinations for prostate cancer. <b>2009</b> , 5, 187-96	22
172	Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. <b>2009</b> , 15, 2148-57	700
171	Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. <b>2009</b> , 6, e1000113	551
170	Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. <b>2009</b> , 183, 937-44	291
169	Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. <b>2009</b> , 15, 7029-35	72
168	TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis. <b>2009</b> , 183, 2321-9	43
167	Modulators of arginine metabolism support cancer immunosurveillance. <b>2009</b> , 10, 1	55
166	Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. <b>2010</b> , 40, 22-35	406
165	Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. <b>2009</b> , 29, 436-71	27
164	Agression of TLR9 in human pulmonary adenocarcinoma cell line A549. <b>2009</b> , 8, 393-396	
163	Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 687-97	7.4 76
162	Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. <b>2009</b> , 85, 996-1004	189
161	Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. <b>2009</b> , 11, 615-28	205
160	Cytokines in the management of high risk or advanced breast cancer: an update and expectation. <b>2009</b> , 9, 888-903	33

159	Myeloid-derived suppressor cells in transplantation. <b>2010</b> , 15, 765-8		23
158	Muscle-derived Gr1(dim)CD11b(+) cells enhance neovascularization in an ischemic hind limb mouse model. <b>2010</b> , 116, 1623-6		21
157	Premetastatic Niches. <b>2010</b> , 161-182		
156	Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?. <b>2010</b> , 9, 519-25		42
155	Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 47-62	7-4	42
154	Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14?/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. <b>2010</b> , 136, 35-45		238
153	Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. <b>2010</b> , 27, 430-3		6
152	Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice. <b>2010</b> , 185, 698-708		24
151	A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. <b>2010</b> , 16, 4583-94		362
150	Myeloid cells in tumour-immune interactions. <b>2010</b> , 4, 315-27		9
149	Pivotal advance: glycyrrhizin restores the impaired production of beta-defensins in tissues surrounding the burn area and improves the resistance of burn mice to <i>Pseudomonas aeruginosa</i> wound infection. <b>2010</b> , 87, 35-41		18
148	Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. <b>2010</b> , 185, 1383-92		197
147	Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. <b>2010</b> , 31, 334-41		109
146	IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice. <b>2010</b> , 22, 245-57		46
145	Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. <b>2010</b> , 70, 6139-49		264
144	Measurement of myeloid cell immune suppressive activity. <b>2010</b> , Chapter 14, Unit 14.17		15
143	Tumour-Induced Immune Suppression by Myeloid Cells. <b>2011</b> , 49-62		
142	Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells. <b>2011</b> , 11, 816-26		61

141	Exosomes and cancer: a newly described pathway of immune suppression. <b>2011</b> , 17, 959-64	212
140	How to improve the immunogenicity of chemotherapy and radiotherapy. <b>2011</b> , 30, 71-82	66
139	Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. <b>2011</b> , 11, 734-51	81
138	The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. <b>2011</b> , 6, 824-33	209
137	Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-intensity electrogenetherapy. <b>2011</b> , 18, 265-74	8
136	Interactions of dendritic cells with cancer cells and modulation of surface molecules affect functional properties of CD8+ T cells. <b>2011</b> , 48, 1744-52	8
135	Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact. <b>2011</b> , 21, 131-8	51
134	Improving cancer immunotherapy by targeting tumor-induced immune suppression. <b>2011</b> , 30, 125-40	115
133	Paired immunoglobulin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. <b>2011</b> , 34, 385-95	117
132	Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. <b>2011</b> , 71, 3505-15	395
131	Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. <b>2011</b> , 3, 77-96	23
130	Suppressive CD8+ T cells arise in the absence of CD4 help and compromise control of persistent virus. <b>2011</b> , 186, 6218-26	38
129	Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. <b>2011</b> , 186, 264-74	46
128	Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. <b>2012</b> , 3, 67	23
127	Myeloid-derived suppressor cells participate in preventing graft rejection. <b>2012</b> , 2012, 731486	9
126	Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. <b>2012</b> , 33, 1231-8	143
125	Phenotypic, morphological, and functional heterogeneity of splenic immature myeloid cells in the host response to tularemia. <b>2012</b> , 80, 2371-81	15
124	Tobacco, inflammation, and respiratory tract cancer. <b>2012</b> , 18, 3901-38	46

123	Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon- $\gamma$ TLR-9 agonist and GM-CSF with peptide vaccination. <b>2012</b> , 35, 702-10		56
122	Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors. <b>2012</b> , 35, 374-84		38
121	Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 1373-85	7.4	187
120	Myeloid-derived suppressor cells from tumor-bearing mice impair TGF- $\beta$ -induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. <b>2012</b> , 92, 987-97		60
119	Very small size proteoliposomes derived from <i>Neisseria meningitidis</i> : an effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions. <b>2012</b> , 30, 2963-72		6
118	Negative regulation of myeloid-derived suppressor cells in cancer. <b>2012</b> , 41, 562-80		29
117	Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness. <b>2012</b> , 5, 34		31
116	Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. <b>2012</b> , 41, 595-613		79
115	Arginase-dependent suppression by CpG-ODN plus IFA-induced splenic myeloid CD11b(+)Gr1(+) cells. <b>2012</b> , 90, 710-21		6
114	Basic concepts in glioma immunology. <b>2012</b> , 746, 42-52		39
113	Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses. <b>2012</b> , 22, 50-9		26
112	Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma. <b>2013</b> , 15, 825-9		20
111	Myeloid-derived suppressor cells: the dark knight or the joker in viral infections?. <b>2013</b> , 255, 210-21		90
110	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation. <b>2013</b> , 597-634		2
109	Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. <b>2013</b> , 191, 4141-51		99
108	Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. <b>2013</b> , 73, 2127-38		82
107	Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion. <b>2013</b> , 13, 3123-31		110
106	The tumor microenvironment: a pitch for multiple players. <b>2013</b> , 3, 90		102

105	Deficiency of Kruppel-like factor KLF4 in mammary tumor cells inhibits tumor growth and pulmonary metastasis and is accompanied by compromised recruitment of myeloid-derived suppressor cells. <b>2013</b> , 133, 2872-83	34
104	Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. <b>2013</b> , 8, e71629	25
103	Advances in Tumor Immunology and Immunotherapy. <b>2014</b> ,	0
102	Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients. <b>2014</b> , 44, 639-50	44
101	Complexity and challenges in defining myeloid-derived suppressor cells. <b>2014</b> ,	82
100	DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. <b>2014</b> , 95, 743-753	38
99	Serum neopterin levels in female dogs with malignant mammary tumours. <b>2014</b> , 12, 143-8	2
98	Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. <b>2014</b> , 33, 527-43	67
97	Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. <b>2014</b> , 74, 104-18	247
96	Novel Technologies for Vaccine Development. <b>2014</b> ,	1
95	Glioma Cell Biology. <b>2014</b> ,	2
94	Properties of human blood monocytes. I. CD91 expression and log orthogonal light scatter provide a robust method to identify monocytes that is more accurate than CD14 expression. <b>2014</b> , 86, 111-20	11
93	BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. <b>2014</b> , 74, 5091-102	82
92	Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism. <b>2014</b> , 63, 456-70	51
91	Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. <b>2014</b> , 16, 234-44	31
90	PGC-1 coactivator activity is required for murine erythropoiesis. <b>2014</b> , 34, 1956-65	19
89	Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination. <b>2015</b> , 10, e0132799	3
88	Chronic Inflammation-Related HPV: A Driving Force Speeds Oropharyngeal Carcinogenesis. <b>2015</b> , 10, e0133681	8

87	Phenylhydrazine administration accelerates the development of experimental cerebral malaria. <b>2015</b> , 156, 1-11	6
86	Complexity and challenges in defining myeloid-derived suppressor cells. <b>2015</b> , 88, 77-91	86
85	Surgical cytoreduction restores the antitumor efficacy of a <i>Listeria monocytogenes</i> vaccine in malignant pleural mesothelioma. <b>2015</b> , 166, 28-35	1
84	Immunology and Immunotherapy of Ovarian Cancer. <b>2015</b> , 413-456	
83	Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. <b>2015</b> , 75, 3456-65	85
82	Anti-breast cancer properties and toxicity of <i>Dillenia suffruticosa</i> root aqueous extract in BALB/c mice. <b>2015</b> , 5, 1018-1026	7
81	Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. <b>2015</b> , 168, 260-7	17
80	Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. <b>2015</b> , 36 Suppl 1, S111-27	34
79	Myeloid-derived suppressor cells in B cell malignancies. <b>2015</b> , 36, 7339-53	45
78	Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. <b>2016</b> , 7, 814-30	16
77	Distinct courses of infection with <i>Leishmania (L.) amazonensis</i> are observed in BALB/c, BALB/c nude and C57BL/6 mice. <b>2016</b> , 143, 692-703	20
76	Oncodynamics: Effects of Cancer Cells on the Body. <b>2016</b> ,	
75	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). <b>2016</b> , 22, 3924-36	197
74	Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment. <b>2016</b> , 380, 253-6	56
73	Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance. <b>2016</b> , 10, 861-70	43
72	Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. <b>2016</b> , 108,	118
71	Immature myeloid-derived suppressor cells: A bridge between inflammation and cancer (Review). <b>2017</b> , 37, 671-683	21
70	Vaccines and Immunostimulants. <b>2017</b> , 1-22	0

69	Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 355-366	7.4	33
68	Cells of the Immune System. <b>2017</b> , 95-201		
67	Immunopathology in Toxicology and Drug Development. <b>2017</b> ,		0
66	The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. <b>2017</b> , 6, 45-60		16
65	Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1 $\beta$ IL8, CXCL5, and Mip-1 $\alpha$ <b>2017</b> , 23, 2346-2355		101
64	Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1 $\beta$ -mediated increase in E-selectin expression. <b>2017</b> , 140, 1370-1383		50
63	Myeloid-derived suppressor cells in ovarian cancer: friend or foe?. <b>2017</b> , 42, 383-389		8
62	Oncolytic viruses as engineering platforms for combination immunotherapy. <b>2018</b> , 18, 419-432		194
61	Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. <b>2018</b> , 11, 27-32		29
60	Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer. <b>2018</b> , 40, 91-97		22
59	Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis. <b>2018</b> , 233, 3024-3036		103
58	Chemokine (C-X-C motif) ligand 1 and CXCL2 produced by tumor promote the generation of monocytic myeloid-derived suppressor cells. <b>2018</b> , 109, 3826-3839		31
57	Endogenous Protection from Ischemic Brain Injury by Preconditioned Monocytes. <b>2018</b> , 38, 6722-6736		34
56	Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells. <b>2018</b> , 9, 1782		58
55	Major fundamental factors hindering immune system in defense against tumor cells: The link between insufficiency of innate immune responses, metabolism, and neurotransmitters with effector immune cells disability. <b>2019</b> , 212, 81-87		4
54	Selenopheno[2,3-f]coumarins: novel scaffolds with antimetastatic activity against melanoma and breast cancer. <b>2019</b> , 43, 11851-11864		5
53	Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. <b>2019</b> , 91, 1319-1328		13
52	Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. <b>2019</b> , 11,		12

51	Targeting Metalloenzymes for Therapeutic Intervention. <b>2019</b> , 119, 1323-1455	109
50	Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer. <b>2019</b> , 234, 3515-3525	42
49	Myeloid-derived suppressor cells and tumor: Current knowledge and future perspectives. <b>2019</b> , 234, 9966-9981	29
48	Chemical characterization and anti-breast cancer effects of silver nanoparticles using Phoenix dactylifera seed ethanolic extract on 7,12-Dimethylbenz[a] anthracene-induced mammary gland carcinogenesis in Sprague Dawley male rats. <b>2020</b> , 34, e5136	20
47	Knockdown of serine/threonine-protein kinase 24 promotes tumorigenesis and myeloid-derived suppressor cell expansion in an orthotopic immunocompetent gastric cancer animal model. <b>2020</b> , 11, 213-228	11
46	Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. <b>2020</b> , 117, 201-215	49
45	Biomaterialized Biohybrid Algae for Tumor Hypoxia Modulation and Cascade Radio-Photodynamic Therapy. <b>2020</b> , 12, 44541-44553	11
44	Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes. <b>2020</b> , 150, 261-280	20
43	Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers. <b>2020</b> , 12,	73
42	Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy. <b>2020</b> , 252, 117646	8
41	The Preliminary Study for Postoperative Radiotherapy Survival Associated with and Expression in Lung Cancer. <b>2021</b> , 13, 4497-4507	1
40	Comments on the ambiguity of selected surface markers, signaling pathways and omics profiles hampering the identification of myeloid-derived suppressor cells. <b>2021</b> , 364, 104347	0
39	Glioblastoma as an age-related neurological disorder in adults. <b>2021</b> , 3, vdab125	5
38	Immune Escape. <b>2005</b> , 43-81	6
37	Myeloid-Derived Suppressor Cells in Cancer. <b>2008</b> , 157-195	2
36	Immune Effector Cells in the Tumor Microenvironment: Their Role in Regulation of Tumor Progression. <b>2008</b> , 1-33	2
35	Cancer-Induced Inflammation. <b>2016</b> , 73-84	1
34	Targeting inflammatory cells to improve anti-VEGF therapies in oncology. <b>2010</b> , 180, 185-200	12



33	Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. <b>2006</b> , 116, 2777-90	637
32	Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. <b>2010</b> , 120, 2486-96	161
31	TNF signaling drives myeloid-derived suppressor cell accumulation. <b>2012</b> , 122, 4094-104	242
30	Tumor growth decreases NK and B cells as well as common lymphoid progenitor. <b>2008</b> , 3, e3180	19
29	Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. <b>2010</b> , 5, e8922	118
28	Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-CSF-expressing plasmid in mice. <b>2012</b> , 7, e34602	13
27	Current perspectives in prostate cancer vaccines. <b>2009</b> , 9, 1052-7	2
26	Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. <b>2012</b> , 18, 3303-9	92
25	Macrophages in tumour development and metastasis. <b>2008</b> , 115-137	
24	Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines. <b>2009</b> , 58, 40-48	
23	Immune Surveillance and Tumor Evasion. <b>2011</b> , 193-210	
22	Utilizing Mouse Models of Human Cancer for Assessing Immune Modulation of Cancer Development. <b>2012</b> , 443-463	
21	Transplantation tolerance. <b>2013</b> , 1034, 85-101	1
20	The Effects of Lycium chinese Mill., Morus alba L. and Their Combination on the Asthmatic Murine Model. <b>2013</b> , 21, 36-50	1
19	The Immune System in Head and Neck Squamous Cell Carcinoma: Interactions and Therapeutic Opportunities. <b>2014</b> , 275-321	
18	The Effects of Sinapis Semen, Raphani Semen, and mixture decoction on the Asthmatic Mouse Model. <b>2013</b> , 28, 15-23	1
17	Myeloid-Derived Suppressor Cells in Tumor-Induced T Cell Suppression and Tolerance. <b>2014</b> , 99-150	2
16	Immune Response: Glioma-Associated Immunosuppression. <b>2014</b> , 221-239	

15	The Use of Oncolytic Herpesvirus for the Treatment of Cancer. <b>2014</b> , 329-345	
14	The Effects of Gamchomahwang-tang extract According to the ratio of 2 compounds on the Ovalbumin-Induced Allergic Asthma in Mice. <b>2015</b> , 28, 74-91	2
13	Endogenous protection from ischemic brain injury by preconditioned monocytes.	
12	Immunology and Immunotherapy of Ovarian Cancer. <b>2020</b> , 487-540	
11	Engineering T Cells to Survive and Thrive in the Hostile Tumor Microenvironment. <b>2021</b> , 100360	1
10	CTLA-4-immunoglobulin and indoleamine 2,3-dioxygenase in dominant tolerance. <b>2008</b> , 87-106	
9	Immunotherapy for advanced prostate cancer. <b>2007</b> , 9 Suppl 1, S29-38	8
8	Cancer vaccines: current directions and perspectives in prostate cancer. <b>2009</b> , 11, 31-6	5
7	Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients. <b>2013</b> , 13, 1	42
6	Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.. <b>2022</b> , 113, 1-57	0
5	Combining Chemotherapy with Immunotherapy in Colorectal Cancer: A Review. <i>Clinical Cancer Drugs</i> , <b>2021</b> , 8, 10-17	0.2
4	DAT and TH expression marks human Parkinson's disease in peripheral immune cells. <i>Npj Parkinson's Disease</i> , <b>2022</b> , 8,	9.7 0
3	The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms. 55,	0
2	TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy. <b>2022</b> , 20,	0
1	A $\alpha$ +2B5 Strategy for Tumor Immune Microenvironment Remodeling Based on Complementary Immune Checkpoint Blockade. <b>2023</b> , 142956	0